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ABSTRACT
CHARACTERIZATION AND INHIBITOR EVALUATION OF ISPD AND ISPE ENZYMES
FROM THE NON-MEVALONATE PATHWAY
Brian E. Hartnett, Ph.D.
Department of Chemistry and Biochemistry
Northern Illinois University, 2016
James R. Horn, Co-Director
Timothy J. Hagen, Co-Director

There is an immediate need for new antibiotics. Antimicrobial resistance is
rising at an alarming rate. In addition, certain select agents are a risk for bioterrorism that
necessitate the discovery of new antibiotics. The methylerythritol phosphate (MEP) pathway is
a metabolic pathway that produces the isoprenoid precursors, isopentyl pyrophosphate (IPP)
and dimethylallyl pyrophosphate (DMAPP). Notably, the MEP pathway is present in most
bacteria and not mammals, which makes the enzymes of the MEP pathway attractive targets for
discovering new anti-infective agents due to reduced chances of off-target interactions leading
to side effects. Currently, there are very few known inhibitors of the 2-C-methyl-D-erythritol
4-phosphate cytidylyltransferase (IspD) and 4-diphosphocytidyl-2-C-methyl-D-erythritol
kinase (IspE) enzymes, with the majority possessing weak potency (IC50 values in the
millimolar range).
The focus of this research examines the biophysical properties of IspD and IspE to aid
discovery of novel inhibitors. Saturation transfer difference nuclear magnetic resonance (STD-

NMR) fragment screening identified several fragments that bound to both IspD from
Mycobacterium paratuberculosis and IspE from Mycobacterium abscessus. Analogs of these

fragments aimed to target IspD and IspE. Thermal shift screening was used as a filter to
identify a subset of compounds that bind to the IspD and IspE enzymes. High throughput
thermal shift screening of the MicroSource Spectrum library against EcIspD revealed several
potential hits, which were subsequently investigated using a plate‐ based enzyme inhibition
assay. Results from the enzyme inhibition assays revealed a small set of compounds capable of
inhibiting IspD activity. Follow-up studies were performed using isothermal titration
calorimetry and enzymatic inhibition assays. Results from these studies have confirmed
compounds with high micromolar inhibition targeting IspD from Escherichia coli. The IspE
enzyme from both Escherichia coli and Burkholderia thailandensis were characterized with
biophysical methods. Additionally, a plate-based enzyme inhibition assay was optimized to
evaluate potential IspE inhibitors, which helped discover several novel inhibitors (IC50 values
in the micromolar range). The identified compounds could be used for future development of
more potent IspD and IspE inhibitors.
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CHAPTER 1

INTRODUCTION

Arguably one of the greatest medical developments is the discovery of antibiotics.
Antibiotics have not only helped increase the average human lifespan and quality of life, but
are also needed as defense against biological select agents and toxins (BSATs).1,2,3 In 1995 a
member of the Aryan Nations obtained Yersinia pestis which prompted Congress to pass the
Antiterrorism and Effective Death Penalty Act.4 This in conjunction with the anthrax attacks in
2001, which killed 5 people, prompted the Center for Disease Control and Prevention (CDC)
and the US Department of Agriculture (USDA) to manage the Federal Select Agent Program
(FSAP) which focuses on the regulation of these select agents.5 Currently there are 65 select
agents, with 11 considered tier one being a subsect that present a prominent risk of potential
mass casualties, which are bacteria, toxins, and viruses that may be purposed as biological
weapons.6,7 Examples of these agents include the Ebola virus, Bacillus anthracis, Yersinia
pestis, and Burkholderia pseudomallei.8
The first true antibiotic was discovered by Alexander Fleming in 1928, and
unbeknownst to him, at the time, he had revolutionized medicine.9 With the establishment of
antibiotics came the generation of antimicrobial resistance. Antibiotic resistance is a
predominant threat within the health care system with estimated costs of greater than $20
billion in the United States alone.10 Antibiotic resistance may evolve through natural selection
with random mutations that are capable of developing a resistance gene that enable the
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bacteria to tolerate antibiotic treatment, and with each antibiotic treatment there is an increase
in the resistant subpopulation until the strain becomes primarily drug-resistant (Figure 1-1).11,12
Due to this resistance, the necessity of new antibiotics in which to fight these resistant
strains of bacterial infections is dire. Despite this fact, since the 1950s, new antibiotic
approvals through the US Food and Drug Administration (FDA) have drastically reduced each
decade, which has culminated in a “discovery void” since the 1990s (Figure 1-2).13 This era is
due to several reasons. One, the tremendous cost of bringing an antibiotic to market and the
inability of a pharmaceutical company to recoup its investment, which in 2015 was estimated to
be about $2.5 billion dollars.14 Additionally, there has been a diminution of new antibiotic
targets, with only the two new classes of developed since the 1960s (Figure 1-3 and Figure 14). 15,16 This reduction in antibiotic development along with the rapid increase in antibiotic
resistance creates a nightmare situation for the overall health of the world, with new resistant
strains and mechanisms spreading globally, making it harder to treat common infectious
diseases. The lack of new antibiotic classes shows why there is a great need and desire to
uncover new targets and scaffolds to combat microbial dissension. Currently, there are three
avenues to approach new antibiotic development: analogs of compounds or use of known
classes that address known targets such as substrates or known inhibitors, discovering new
compounds with new mechanisms of action within new classes that act on known targets, and
finally new compounds within new classes acting on novel targets.17,18

3

Figure 1-1 Evolution of a drug resistant strain of bacteria. Adapted from CDC antibiotic threat report, 2013.10

3

4

Figure 1-2 Discovery timeline of new antibiotic classes and introduction of the “Discovery Void”.13

4

5

Figure 1-3 Examples of several major classes of antibiotics.16
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Figure 1-4 More examples of major classes of antibiotics. Two newest classes highlighted
in red.16

7

Antibacterial Targets

The discovery void of new antibiotic classes and targets is significant, essentially all
new antibiotics that have been developed in the latter half of the 20th century have been based
off current antibiotic classes.15, 19 This is a testament to the difficulty of producing novel
antibiotics, especially with unique mechanisms of action.20 Each antibiotic class has a core
structure, related to its mode of action, with family members in the class possessing
modifications around the core (Figure 1-5). One example, the quinolone family, was first
introduced to the clinic in 1967, which spawned four generations of antibiotics and over 10,000
analogs of the quinolone core.21,22,23 The different classes are commonly associated with their
target such as cell wall biosynthesis, protein synthesis, DNA and RNA synthesis, folate
synthesis, and disruption of cell membranes. Targeting and inhibiting these pathways halts a
metabolic process that can lead to cell death (Figure 1-6).13,24

8

Figure 1-5 Generations of fluoroquinolone family of compounds with quinolone core.

9

Figure 1-6 Major antibiotic pathways to target for drug development. Adapted from Walsh. 18
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Targeting Cell Wall Synthesis

One of the most common pathways for antibiotic development includes inhibiting the
synthesis of bacterial cell walls along with their structural integrity. This strategy has worked
well, as most bacteria possess a peptidoglycan cell wall while eukaryotic cells do not.25
Peptidoglycans are polymers of disaccharides which are cross-linked by pentapeptide side
chains.26 These polymers are maintained by a series of enzymes including transpeptidases,
such as DD-transpeptidases, which are targets for a number of antibiotics. Transpeptidases are
a member of the transferase family of enzymes are involved in the crosslinking of the
disaccharides.27 β-lactams, such as penicillin and its analogs, monobactams, cephalosporins
and carbapenems target these transpeptidases by imitating the D-Alanine-D-Alanine dipeptide
of the pentapeptides which is the substrate for such enzymes (Figure 1-7A).28,29 The serine
within the transpeptidases reacts with the carboxylate group on the β-lactam, the sulfonate
group upon monobactams, which cause the enzyme to become acylated and thereby inactive
(Figure 1-7B).30,31,32 Inhibitors of these DD-transpeptidases prevent the creation of
peptidoglycans causing the cell wall to be permeable which will leak ATP and potassium along
with losing the cell wall potential leading to cell death.33,34

9

11

A

B
Figure 1-7 Mechanism of action of β-Lactams. (A) Penicillin mimics the D-Ala-D-Ala substrate for the transpeptidases. (B)
Serine within the transpeptidases covalently link to the β-lactam rendering it inactive.28,30

11
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Inhibition of Protein Synthesis

The synthesis of proteins within the ribosome of the bacteria, is currently what the
majority of antibiotics target. The genetic information of bacteria, stored in the sequences of
deoxyribonucleic acid (DNA),35 is transcribed into messenger ribonucleic acids (mRNAs) by
ribonucleic acids (RNA) polymerases, which are ultimately translated into the corresponding
polypeptide chains by ribosomes and other contributing cytoplasmic factors. There are three
phases in the translation process that may be targeted: initiation, elongation and
termination.36,37 Ribosomes are made up of two subunits, a larger 50s and a smaller 30s, which
associate at the initiation step of translation (Figure 1-8).
Antibiotics targeting initiation at the ribosome includes compounds such as macrolides,
lincosamides, aminoglycosides, tetracyclines, chloramphenicol, streptogramins, and
oxazolidinones.20,38,39,40 The messenger RNA decoding region of ribosomal RNA within the
30s subunit of the ribosome is targeted by aminoglycosides which will create misreading of
RNA codons and early chain termination, and tetracyclines which block the introduction of
new amino acids to the peptide chain.40,41,42,43 A greater number of antibiotics target the 50s
subunit than the 30s subunit, such as, transfer ribonucleic acid (tRNA) blocking macrolides and
lincosamides, mRNA blocking chloramphenicols, streptogramins composed of a component A
(cyclopeptides with multiple conjugated double bonds) which block substrate sites and
component B (cyclic hexadepsipeptides) that prevents the creation/completion of polypeptide
chains, and initiation complex blocking oxazolidinones.39,44,45,46,47 Each of these antibiotic’s
actions can prompt translation miscues, halting initiation, which leads to cell death.48

11
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13

Figure 1-8 Inhibition of protein synthesis by various antibiotics. Adapted from Marieb.48

14
Inhibition of DNA or RNA Synthesis

Another pathway taken is impeding DNA replication and RNA transcription.
Quinolones and fluoroquinolones directly inhibit DNA synthesis by targeting both DNA gyrase
(topoisomerase II) and topoisomerase IV. DNA gyrase and topoisomerase IV are involved
with supercoiling and relaxing DNA which promotes movement to the replication forks.49
Quinolone-based antibiotics bind to the enzyme-DNA complex, forcing the enzyme to undergo
a conformational change, which prevents re-ligation of the DNA after topoisomerase-driven
cleavage, causing the isomerase to be covalently attached on the DNA.23,50
RNA polymerase is the enzyme involved in transcription of DNA to RNA. The
polymerase uses DNA as at template to transfer the genetic information into RNA.51
Rifamycins interfere with the polymerase at the initiation step of RNA synthesis by blocking
the binding of the polymerase to the template. Disrupting DNA synthesis or RNA transcription
could lead to cell death (Figure 1-9).52

13

15

15

Figure 1-9 Quinolones, fluoroquinolones and rifamycins targets for DNA and RNA inhibition. Adapted from Diacon.52

16
Inhibiting Folate Synthesis

Folate is a compound necessary for cell division, DNA and RNA synthesis and
methylation of DNA.53 Humans are unable to synthesize folates de novo; however, bacteria
have the ability to biosynthetically create DNA bases from para-aminobenzoic acid (PABA)
and pteridine.54 Sulfonamides disrupt folate synthesis by competing for the active site of
dihydropteroate synthetase, which is the first enzyme in the pathway of converting PABA into
purines and pyrimidines.53,55,56 Trimethoprim prevents the reduction of dihydrofolic acid to
tetrahydrofolic acid by inhibiting dihydrofolate reductase. This antibiotic is often used in
conjunction with the sulfonamide, sulfamethoxazole, in order to target both enzymes
simultaneously (Figure 1-10).57,58,59 Blocking of folate synthesis at any step will prevent the
bacteria from maintaining and synthesizing DNA and RNA rendering the organism unable to
transfer genetic material, leading to cell death.60,61

17

Figure 1-10 Folate synthesis pathway showing the creation of DNA bases from
para-aminobenzoic acid (PABA). Sulfonamides and trimethoprim inhibit at two
different enzymes as shown. Adapted from Basset.59

18
Cell Membrane Disruption

Possibly the most recent of pathways used for antibiotic development, is disruption of
cellular membranes. These membranes are compiled of proteins and phospholipids, which
allow selective permeability where bacteria take in nutrients and dispel out waste. Disturbing
this balance between nutrient and waste, through compromising the integrity of the cell
membrane, is a suitable approach for antibiotics, which can lead to cell death (Figure 1-11).62
Daptomycin is a cyclic lipopeptide which inserts into the cell membrane, with aid of calcium,
and binds to the phosphatidylglycerol groups.63,64 Once inserted into the bacterial membrane
there is a conformational transition and oligomerization of the peptide causing a rapid
depolarization of the membrane, ultimately resulting in cellular leakage, (e.g., potassium ions)
and interference with the membrane role in cell division.65
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Figure 1-11 Mechanism of action of daptomycin creating channels and potassium efflux. Adapted from Steenbergen. 64
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Strategies for Combatting Antibiotic Resistance

Due to overuse and incorrect use of antibiotics, bacteria have developed resistance
against most classes of antibiotics. Bacteria continue to mutate and develop resistant genes.
These genes may code for resistance in three primary ways. First, bacteria may develop efflux
pumps that transport antibiotics out of the cell.66 Second, bacteria may develop methods to
degrade these antibiotics enzymatically. Finally, these bacteria create ways to chemically
change and inactivate the antibiotic.67 With these forms of resistance happening at an
exponential rate in conjunction with the reduction of research into developing new classes of
antibiotics, there is a race that bacterial infections are winning. Discovering unique classes and
mechanisms of action is a necessity for fighting back.

MEP Pathway Enzymes as Unique Targets

Relatively all living organisms rely on isoprenoid biosynthesis, including pathogenic
organisms. Isoprenoids, also known as terpenoids, are a large family of over 35,000 distinct
compounds, which contribute to biological processes ranging from electron transport, such as
ubiquinone, to building cell membrane components, such as cholesterol (Figure 1-12).68,69 This
wide range of isoprenoids’ lineage can be traced back to two 5-carbon intermediates;
isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP). These
isoprenoids can be generated through two separate pathways. The mevalonate dependent
(MVA) pathway is found in eukaryotes, archaea, and some plants and bacteria, while the 2Cmethyl-D-erythritol 4-phosphate (MEP) pathway is found in bacteria, higher plants, and
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malarial parasites. Interestingly, the MEP pathway it is not found in mammals, making it an
attractive target for novel antibiotics.70

22

Figure 1-12 Isoprenoid development from isopentyl pyrophosphate (IPP) and
dimethylallyl pyrophosphate (DMAPP). Adapted from Simon. 66
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Isoprenoid Biosynthesis Via the Mevalonate Dependent Pathway

The mevalonate pathway, also known as the 3-hydroxy-3-methyl-glutaryl-coenzyme A
(HMG-CoA) reductase pathway, converts acetyl coenzyme A (Acetyl-CoA) to IPP via six
enzymatic steps (Figure 1-13).71 The first step involves acetoacetyl-CoA thiolase catalyzing
the condensation of two acetyl-CoA into acetoacetyl-CoA. The enzyme 3-hydroxy-3methylglutaryl coenzyme A (HMG-CoA) synthase condenses the acetoacetyl-CoA with an
additional acetyl-CoA into the product HMG-CoA. This product is converted to the pathway’s
namesake substrate, mevalonate, via the enzyme HMG-CoA reductase. The next two steps add
the pyrophosphate to the mevalonate using the enzymes: mevalonate-5-phosphate kinase and
phosphomevalonate kinase. The final step converts the mevalonate pyrophosphate substrate to
the isoprenoids IPP and DMAPP.72
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Figure 1-13 Biosynthesis of isoprenoid precursors via the mevalonate dependent pathway.
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Isoprenoid Synthesis Via an Alternative 2C-methyl-D-erythritol 4-phosphate Pathway

The more recently discovered 2C-methyl-D-erythritol 4-phosphate (MEP) pathway,
which was first observed in bacteria in 1988, is also known as the 1-deoxy-D-xylulose 5phosphate (DOXP) pathway, and synthesizes both IPP and DMAPP isoprenoids in 7 steps
beginning with the reactants pyruvate and glyceraldehyde-3-phosphate (Figure 1-14).73 The
pathway initiates with DOXP synthase converting the pyruvate and glyceraldehyde-3phosphate into DOXP. DOXP reductoisomerase (IspC) then reduces the product to the
pathway’s designated MEP. Cytidine monophosphate (CMP) is added to the MEP by the
enzyme 2C-methyl-D-erythritol 4-phosphate cytidylyltransferase (IspD) to create the substrate
4-diphosphocytidyl-2-C-methyl-D-erythritol (CDP-ME). The enzyme 4-diphosphocytidyl-2-Cmethyl-D-erythritol kinase (IspE) will phosphorylate the CDP-ME to create the substrate 4diphosphocytidyl-2-C-methyl-D-erythritol 2-phosphate (CDP-MEP) which is cyclized into the

product 2C-methyl-D-erythritol 2,4-cyclodiphosphate (MEcDP) with the release of CMP
catalyzed by the 2-C-methyl-D-erythritol 2,4-cylcodiphosphate synthase (IspF) enzyme. The
ring-shaped product MEcDP undergoes a reduction to (E)-4-hydroxy-3-methylbut-2-enyl
diphosphate (HMBDP) through the enzyme 4-hydroxy-3-methylbut-2-en-1-yl diphosphate
synthase (IspG). The final step in this pathway converts the HMBDP into IPP and
consequently DMAPP via the 4-hydroxy-3-methylbut-2-enyl diphosphate reductase (IspH)
enzyme.74,75 These enzymatic steps open new windows of opportunity for druggable targets,
which are targets that small molecule inhibitors will likely bind to, with minimum human
toxicity due to no overlap in the pathways.
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Figure 1-14 Isoprenoid biosynthesis via the methylerythritol phosphate pathway.
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Targeting IspD

The third enzyme in the MEP pathway, IspD, catalyzes the conversion of MEP to CDPME by transferring the CMP from cytidine triphosphate (CTP) to the phosphate on the MEP,
releasing pyrophosphate (Figure 1-15).76 This step could be an ideal target to develop
inhibitors that could lead to antibacterial or even herbicide agents. Currently, there are 35
crystal structures of IspD from 13 different species possessing 31 different ligands deposited in
the protein database (PDB). Most notably, a crystal structure of IspD bound to CTP and the
reaction product CDP-ME, allow insight in the structure of the active site.69, 77
IspD is proposed to be active as a dimer with the subunits consisting of a seven strand
β-sheet with an α/β structure around it and an arm-like loop that interacts with its neighboring
monomer to form the observed homodimer (Figure 1-16).78 Within the face of the dimer
interface, there is a highly conserved active site between species, specifically when comparing
the sequences of Escherichia coli, Burkholderia thailandensis, Mycobacterium tuberculosis,
and Arabidopsis thaliana (Figure 1-17). Despite the presence of any direct interactions with
IspD residues, a divalent metal ion (most often Mg2+) is necessary for the activity of the
enzyme and is found coordinated to the α, β, and γ phosphates of CTP, likely stabilizing the
reaction intermediate (Figure 1-18). Along with the Mg2+, residues Lys-27 and Lys-213 aid in
the coordination of the phosphates and are conserved across different species.77 The base
binding pocket is also conserved within the active site involving hydrogen bonds being formed
between the backbone amides from Ala-14 and Ala-15 with B. thailandensis having a cysteine
instead of an Ala-14. The carbonyl oxygen of Gly-82 also creates hydrogen bonds and Asp-83
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in E. coli, however, Asp-83 is not conserved between species. The hydroxyl groups of the
ribose ring coordinate with Pro-13, Gly-16 and Ala-107 which are completely conserved
between E. coli, B. thailandensis and M. tuberculosis, Pro-13 and Ala-107 are Val-13 and Ser107 respectively for A. thaliana.79

Figure 1-15 Third step in the MEP pathway. IspD catalyzes the cytidylation of MEP converting it to CDPME.
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Figure 1-16 Ribbon representation of Ec IspD dimeric crystal structure. IspD is co-crystalized with product CDP-ME (red)
and metal cofactor Mg2+ (PDB: 1INI).77
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Figure 1-17 Sequence homology of IspD. The species Escherichia coli, Burkholderia
thailandensis, Mycobacterium tuberculosis and Arabidopsis thaliana’s full sequence
homology is observed to be 47%, however, active site residues are highly conserved
between species.
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Figure 1-18 Active site of IspD. E. coli in green and B. thailandensis in cyan highlighting Lys-27 and Mg2+ coordinating with
the phosphates of the product CDP-ME. Ala-15, Ser-88, Gly-82 and Asp-83 coordinate with the cytidine base and Gly-16 and
Pro-13 bind with the hydroxyls on the ribose ring (PDB: 1INI).
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Targeting IspE

The fourth enzyme in the MEP pathway (IspE) catalyzes the adenosine triphosphate
(ATP) dependent phosphorylation of CDP-ME to CDP-MEP (Figure 1-19).80 This kinase is
also an attractive target for inhibition to disrupt the biosynthesis of isoprenoids. To date, there
are 17 crystal structures of six different species of IspE deposited in the PDB with 17 different
ligands.
IspE is commonly reported as a homodimer, with each monomer comprising of 10 αhelices and 12 β-sheets. Monomers dimerize with salt bridges formed between Arg-21 of one
monomer and Asp-80 on the other monomer, along with hydrogen bonds formed between the
amide of Gly-87 and the carbonyl of Ala-22. The dimer results in a solvent-filled channel with
active sites at each end of the channel. Each subunit has two domains; one domain provides a
binding site for ATP, the second provides a binding site for the substrate CDP-ME (Figure 120).81
Active sites are highly conserved between species, with 100% sequence homology in
the CDP-ME binding site and a 75% sequence homology in the ATP binding site between E.
coli and B. thailandensis IspE (Figure 1-21). The ATP binding subunit comprises of a purine
binding pocket which involves hydrogen bonding to Asn-65 and Asn-110 on either side of the
adenine base along with Leu-66 and Lys-96. The ribose ring and phosphates are solvent
exposed with the phosphate portion forming hydrogen bonds with the amides in a glycine rich
loop (Gly-103, Gly-105 and Gly-107) and Ser-108.82
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The second subunit, in which CDP-ME binds to, comprises of two aromatic side chains
(Phe-185 and Tyr-25) in which the cytosine portion of the CDP-ME will coordinate in between
along with hydrogen bonds with His-26. The ribose ring and phosphates are again solvent
exposed with the α and β-phosphates of the CDP-ME directed to the γ-phosphate of the ATP.
The oxygen linker between the α and β-phosphates of the CDP-ME is coordinated by a
hydrogen bond with Ala-140. Hydrogen bonding with the hydroxyl on the methylerythritol
involves Asp-141, Lys-10 and Asn-12 (Figure 1-22).80

Figure 1-19 Phosphorylation of CDP-ME to CDP-MEP by IspE with ATP in the fourth enzymatic step in the MEP pathway.
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Figure 1-20 Crystal structure of Ec IspE co-crystalized with CDP-ME (Cyan) and ATP (Orange). (PDB: 2WW4 and 1OJ4)
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Figure 1-21 Sequence homology of IspE between species. Escherichia coli, Burkholderia
thailandensis, Mycobacterium tuberculosis and Lycopersicon esculentum’s full sequence
homology is observed to be 40%, however, active site residues are highly conserved
between species.
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Figure 1-22 Adjacent binding sites: CDP-ME (Magenta) and ATP (Cyan). Red indicates Bt IspE residues which there are
currently no crystal structures for. PDB: 2WW4 and 1OJ4
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Dissertation Overview

This dissertation aims to characterize the structural and biophysical properties of both
IspD and IspE enzymes. These investigations will aid in the identification and classification of
inhibitors with the long-term goal of interrupting the production of the isoprenoid precursors
IPP and DMAPP. This dissertation will describe the characterization of the IspD enzyme from
the species E. coli and B. thailandensis through the development and optimization of thermal
stability assays, isothermal titration calorimetry (ITC), and enzymatic assays (Chapter 2). The
high throughput thermal stability assays of Ec IspD were used to assess binding potencies of
over 2,700 biologically active and structurally diverse compounds that are either known drugs,
experimental bioactive agents, or pure natural products. The compounds that had a thermal
shift, indicating some interaction, were evaluated further with an enzymatic assay to determine
activity against Ec IspD (Chapter 3). Finally, the same techniques were used to study IspE
from both E. coli and B. thailandensis with the focus of future inhibitor design (Chapter 4).

CHAPTER 2

BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF ISPD AND

EVALUATION OF INHIBITORS

Currently, there are no drugs approved targeting the MEP pathway. Furthermore, very
few inhibitors of the IspD enzyme are known (Figure 2-1)83. Fosmidomycin (1), which is
currently in clinical trials against IspC in P. falciparum, displays competitive inhibition against
IspD in E. coli with an IC50 of 20 mM. 80,84,85 L-erythritol-4-phosphate (2) mimics the IspD
substrate (MEP) having competitive inhibition with an IC50 of 1.36 mM.86 IspD inhibitors have
selective inhibition between species. Interestingly, two IspD inhibitors have displayed
selective inhibition between species. Compound 3 is a potent inhibitor against P. falciparum,
with an IC50 of 47 nM, while in E. coli showed no inhibition up to 30 μM.73 Compound 4
proved to be a potent inhibitor of A. thaliana, with an IC50 of 140 nM and not E. coli. Structural
studies reveal 4 is an allosteric inhibitor rather than a competitive inhibitor.87 Compounds 5, 6
and 8 have shown good potency against A. thaliana, P. vivax and M. smegmatis, however none
showed any activity against E. coli or B. thailandensis.88,89,90,88-89, 91 Compound 7 was chosen
based on a screening selection of absorption, distribution, metabolism, and excretion toxicity
(ADMET) properties using M. tuberculosis.92
As shown, there is a great need for discovering new inhibitors of this enzyme
due to the lack of potent inhibitors, specifically against E. coli and B. thailandensis. Binding
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activity along with enzymatic activity of compounds can be determined with a variety of
methods but each has limitations, consequently, the use of multiple techniques often proves
most useful. Here, thermal stability assays, isothermal titration calorimetry, and enzymatic
activity assays will be used to assess potential small molecule inhibitors. Thermal stability
assays give insight of how compounds may influence protein stability due to ligand
interactions.93,94 However, thermal stability assays do not provide information on the location
of the binding site, nor does binding equate to inhibition of enzymatic activity.95 Isothermal
titration calorimetry (ITC) can provide the thermodynamic parameters of the ligand-enzyme
interaction, including K, Gº, Hº, Sº, and the binding stoichiometry. However, as with most
techniques, the ability to obtain weak binding affinity dissociation constants (KD values in mM
range) with ITC it is limited by the small molecule solubility, as well as the amount of sample
required per titration. Finally, enzymatic inhibition activity assays reveal the key property, the
ability of a compound to inhibit the enzyme. Such assays can also be run in a high throughput
fashion, however, limitations arise due to the expensive substrates and timely experiments.
This chapter will evaluate a series of compounds against IspD from E. coli and B. thailandensis
using these techniques and discuss the results.
The series of compounds were based off fragment hits from a STD-NMR
screening performed by Dr. Darren Begley (SSGCID). This technique studies the interactions
between proteins and ligands with the nuclear Overhauser effect (NOE) by selectively
saturating protons within the protein without the ligand which creates a reference spectrum.96
If a ligand binds to the protein, spin diffusions will cause the saturation to disperse to the
ligand, which would reduce the signal. Subtracting the resulting spectrum from the reference

42
spectrum provides a spectrum for the binding ligands showing which portion of the ligand are
interacting with the protein.97,98
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Figure 2-1 Known inhibitors of the IspD enzyme.85,86,73,87,88,90,92,91
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Methods
Expression of Escherichia coli (Ec) and Burkholderia thailandensis (Bt) IspD77

The gene of EcIspD, in the parent vector pET-14b with the restriction enzymes BgI II at
the 5’ and the NcoI at the 3’ and a hexahistidine peptide tobacco etch virus affinity ((His)6TEV) tag at the N’-terminal (obtained from Odom lab) was transformed into BL21(DE3)
competent cells. The gene of Bt IspD was obtained from the SSGCID (ButhA.00168.a) within
the AVA0421 vector (a pET-14b derivative), which possesses ampicillin resistance and a N’terminal (His)6 -3C tag.99 The sequences of the vectors and genes were verified at University of
Chicago CRC-DNA sequencing facility (Table 2-1). Once transformed with the respective
plasmids, the cells are grown on a Lysogeny broth (LB) agar plate with 100 µg/mL ampicillin
(amp). A single colony was selected and added to 5 mL of LB with 100 µg/mL amp and grown
overnight at 37°C with shaking (235 rpm). A 50 mL subculture was inoculated using the 5 mL
overnight culture, which was subsequently used to inoculate a 1 L LB/amp culture. Cells were
grown at 37°C at 235 RPM until the optical density at 600 nm (OD600), determined with a
Novaspec® II visible spectrophotometer (Pharmacia Biotech), reached a mid-log phase reading
0.5-0.8. Once at mid-log phase, the cells were induced with 1 mM IPTG for 16 hours at 8°C at
235 RPM.76 The cells were pelleted via centrifugation at 8,000 RPM for 15 minutes and stored
at -20°C.

Table 2-1 Verified DNA and protein sequences of both Escherichia coli IspD and Burkholderia thailandensis IspD

Ec IspD

Bt IspD

DNA Sequence

DNA Sequence

ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCA
GGGTCCTGGTATGAGCCTGGCGACCACCCATCTGGATGTGTGCGCGGTGG
TGCCGGCGGCGGGCTTTGGCCGCCGCATGCAGACCGAATGCCCGAAACA
GTATCTGAGCATTGGCAACCAGACCATTCTGGAACATAGCGTGCATGCGC
TGCTGGCGCATCCGCGCGTGAAACGCGTGGTGATTGCGATTAGCCCGGGC
GATAGCCGCTTTGCGCAGCTGCCGCTGGCGAACCATCCGCAGATTACCGT
GGTGGATGGCGGCGATGAACGCGCGGATAGCGTGCTGGCGGGCCTGAAA
GCGGCGGGCGATGCGCAGTGGGTGCTGGTGCATGATGCGGCGCGCCCGT
GCCTGCATCAGGATGATCTGGCGCGCCTGCTGGCGCTGAGCGAAACCAG
CCGCACCGGCGGCATTCTGGCGGCGCCGGTGCGCGATACCATGAAACGC
GCGGAACCGGGCAAAAACGCGATTGCGCATACCGTGGATCGCAACGGCC
TGTGGCATGCGCTGACCCCGCAGTTTTTTCCGCGCGAACTGCTGCATGATT
GCCTGACCCGCGCGCTGAACGAAGGCGCGACCATTACCGATGAAGCGAG
CGCGCTGGAATATTGCGGCTTTCATCCGCAGCTGGTGGAAGGCCGCGCGG
ATAACATTAAAGTGACCCGCCCGGAAGATCTGGCGCTGGCGGAATTTTAT
CTGACCCGCACCATTCATCAGGAAAACACC

ATGGCTCATCACCATCACCATCATATGGGTACCCTGGAAGCTCAGACCCA
GGGTCCTGGTTCGATGGTGACCTCCCGACTCTTCGCCCTGATTCCGTGCG
CCGGCACCGGCAGCCGCTCCGGCTCGGCATTGCCGAAGCAATACCGCAC
GCTCGCCGGCCGCGCGCTCCTGCATTACACGCTCGCCGCGTTCGACGCGT
GCAGCGAGTTCGCGCAAACGCTCGTCGTGATTTCCCCCGACGACGCCCA
CTTCGACGCCCGCCGCTTTGCCGGTCTGCGCTTCGCGGTGCGGCGCTGCG
GCGGCGCGTCCCGACAGGCGTCGGTGATGAACGGGCTGATCCAGCTCGC
CGAATTCGGCGCGACGGACGCCGACTGGGTGCTCGTGCACGACGCCGCG
CGCCCCGGCATCACGCCGGCGCTGATCCGCACGCTGATCGGCGCGCTGA
AGGACGACCCCGTCGGCGGCATCGTCGCGCTGCCGGTCGCCGATACGCT
CAAGCGCGTGCCGGCGGGCGGCGACGCGATCGAGCGCACCGAATCGCG
CAACGGCCTCTGGCAGGCGCAGACGCCGCAGATGTTCCGCATCGGCATG
CTGCGCGACGCGATCCAGCGCGCGCAGCTCGAAGGTCGCGATCTGACCG
ACGAAGCGAGCGCGATCGAATGGGCGGGCCATACGCCGCGCGTCGTGCA
GGGCAGTCTGCGCAACTTCAAGGTCACGTACCCGGAGGATTTCGACCTCG
CGGAGGCGATTCTCGCGCATCCGGCGCGCGCCAGT

Protein Sequence

Protein Sequence

MAHHHHHHMGTLEAQTQGPGMSLATTHLDVCAVVPAAGFGRRMQTECPK
QYLSIGNQTILEHSVHALLAHPRVKRVVIAISPGDSRFAQLPLANHPQITVVDG
GDERADSVLAGLKAAGDAQWVLVHDAARPCLHQDDLARLLALSETSRTGGI
LAAPVRDTMKRAEPGKNAIAHTVDRNGLWHALTPQFFPRELLHDCLTRALN
EGATITDEASALEYCGFHPQLVEGRADNIKVTRPEDLALAEFYLTRTIHQENT

MAHHHHHHMGTLEAQTQGPGSMVTSRLFALIPCAGTGSRSGSALPKQYRTL
AGRALLHYTLAAFDACSEFAQTLVVISPDDAHFDARRFAGLRFAVRRCGGAS
RQASVMNGLIQLAEFGATDADWVLVHDAARPGITPALIRTLIGALKDDPVGGI
VALPVADTLKRVPAGGDAIERTESRNGLWQAQTPQMFRIGMLRDAIQRAQL
EGRDLTDEASAIEWAGHTPRVVQGSLRNFKVTYPEDFDLAEAILAHPARAS
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Purification of Escherichia coli (Ec) and Burkholderia thailandensis (Bt) IspD77

The frozen cells were resuspended in 10 mM Trishydroxyaminomethane (TRIS) buffer
and lysed by sonication using a Digital Sonifier 450® (Branson) for six cycles of 20 seconds
on/60 seconds off. Once sonicated, the sample was centrifuged at 15,000 RPM for 20 minutes
at 4°C to separate the cell remains and insoluble proteins from the soluble fraction containing
IspD. The supernatant was loaded onto a HisTrap HP nickel affinity IMAC column (GE
Healthcare Life Sciences) using a BioLogic LP (Bio-Rad Life Sciences) fast protein liquid
chromatography (FPLC) systems. The loading buffer was 20 mM imidazole, pH 8.0, 50 mM
sodium phosphate, 500 mM NaCl, and 1 mM dithiothreitol (DTT). The protein was eluted
using a linear gradient of elution buffer (500 mM imidazole, pH 8.0, 50 mM sodium phosphate,
500 mM NaCl, and 1 mM dithiothreitol (DTT).91 The fractions containing the IspD enzyme
were combined and purified further with a Superdex 75 HiLoad 26/60 size exclusion column
(GE Healthcare Life Sciences) using 20 mM TRIS, 150 mM NaCl and 1 mM DTT.

Thermal Stability Determined Using Circular Dichroism

Protein secondary structure can be observed using far ultra-violet (UV) circular
dichroism (CD)100,101. This method measures the difference between the right and left-handed
circularly polarized light in the far UV range (190-250 nm). By following the observed loss of
signal related to secondary structure as the temperature was increased, the percent of protein in
the native or unfolded form was determined (Figure 2-2).
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All protein samples were dialyzed overnight in 4 L of 20 mM sodium phosphate with
150 mM NaCl at pH 7.0. CD experiments were performed using a Circular Dichroism
Spectrophotometer 215 (AVIV Biomedical) with a quartz cuvette containing a 1 mm path
length. Wavelength scans were determined from 200 to 250 nm at 25o C, both before and after
thermal unfolding. Thermal unfolding scans were read at either 208 nm for Ec IspD or 218 nm
for Bt IspD over the temperature range of 25 to 100o C at 1o C increments and a temperature
equilibrium time of one minute, with a bandwith of one nanometer and an averaging time of
one second. OriginPro 8 Boltzmann fit was used to determine the melting temperature (Tm) of
each protein.
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Figure 2-2 Thermal stability using CD. A) Wavelength scans showing a reduction of signal indicating loss of secondary
structure. B) Loss of secondary structure as temperature increases designates the fraction of the protein unfolded.
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Thermal Stability Determined Using Differential Scanning Fluorimetry

While CD is a useful technique for observing thermal unfolding of proteins, there are
limitations. One of the greatest limitations is that CD typically allows only one sample to be
run at a time, and each sample can take several hours to run. Differential scanning fluorimetry
(DSF) can follow thermal unfolding of multiple protein samples, at lower volumes, and at a
much faster rate than CD. Similar to a CD observed protein thermal melt, DSF will determine
the fraction of protein in native and unfolded forms. However, while CD directly measures the
protein itself, DSF measures fluorescence of a reporter dye. As a protein unfolds, hydrophobic
residues are exposed that interact with the added dye, causing a change in the dye molecule’s
fluorescence emission profile. The point of 50% native and 50% unfolded is the considered the
melting temperature of the protein.102
Ligand-protein binding events can be evaluated using DSF by observing the change in
melting temperature in the presence and absence of ligand.103 If a ligands presence increases
the melting temperature, the ligand is considered to be a stabilizing compounds, which most
often suggests binding to the native form. A decrease in melting temperature would indicate a
destabilization of the protein. While the observation of thermal stabilization indicates binding,
it does not reveal where the compound binds, whether it binds to the active site, an allosteric
site, or even a crevice on the protein surface unrelated to enzyme activity; each would result in
stabilization of the protein’s native state.
All DSF experiments were performed in 50 mM phosphate buffer at pH 7.4, 150 mM
NaCl, 1x SYPRO orange, 2% DMSO and 200 to 1000 nM of the enzyme with a total volume of
25 µL. Final enzyme concentrations used were 2.0 μM for Ec IspD and 0.5 μM for Bt IspD.
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Samples were measured on a Bio-Rad iQ5 Real-Time PCR (Bio-Rad Life Sciences) using a
temperature range of 25 to 95o C at a rate of 1o C per minute with the fluorescence measured
every 0.5o C every 10 seconds with wavelengths of 530 and 570 nm used for excitation and
emission, respectively. The melting temperature (Tm value) was determined from the first
derivative of the graph of relative fluorescence units vs. temperature.

Binding Studies with Isothermal Titration Calorimetry

Binding studies are essential for determining what type of affinity a protein has for a
ligand. Isothermal titration calorimetry (ITC) allows the ability to determine the binding
affinity (KB) which is characterized as the ratio of the protein (or macromolecule) ligand
complex concentration [ML] by the concentration of free macromolecule [M] and ligand [L], as
presented in the following equation:
[ML]

K B = [M][L].

Eq. 2-1

The equilibrium dissociation constant (KD) can be obtained by taking the inverse of the binding
affinity constant:

KD =

1
KB

.

Eq. 2-2

Along with the binding affinity, the enthalpy change (ΔHºobs) and stoichiometry (n) are
determined directly from an ITC experiment, which also allows calculation of the change in
entropy (ΔSºobs).
ITC studies were performed with a Microcal VP-ITC titration calorimeter (Malvern
Instruments). Proteins were dialyzed overnight against four liters of buffer (20 mM sodium
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phosphate, 150 mM NaCl, pH 7.4). Compounds were dissolved in DMSO and brought to
concentration with the dialysis buffer, with a maximum DMSO concentration of 10% by
volume, and centrifuged at 10,000 RPM for 10 minutes. DMSO concentrations were matched
between the protein and ligand. The dialysis buffer was used for all sample dilutions to ensure
buffers matching between the titrant and titrate, thus minimizing the excess heat due to buffer
mismatch. The Pace method was utilized for the determination of the extinction coefficients at
280 nm for Ec IspD (30,940 M-1 cm-1) and Bt IspD (41,940 M-1 cm-1). Cytidine triphosphate’s
extinction coefficient was 9,100 M-1 cm-1.104 The absorbance values of protein and CTP
solutions were determined using the NanoDrop (in triplicate). All other compound
concentrations were determined by dry weight. ITC experiments were performed with IspD in
the cell and ligand in the syringe, which is at 100 times the concentration of the sample in the
cell due to the low predicted affinities for IspD.105
The initial injection volume was 2 µL (omitted) followed by 27 10 µL injections, every
240 seconds. Samples were run at 25°C, at pH 7.4, with a stirring speed of 307 RPM. Dilution
runs were performed to allow determination of background heats caused by solution mismatch
and instrument noise. Dilution runs were performed with ligand (at the same concentration as
in the experiment run) in the syringe titrated into the dialysis buffer in the cell. Data were fit
using OriginPro 7 with the ITC add-on by the manufacturer.

Enzyme Inhibition Determined Using EnzChek® Phosphate Assay Kit106

Thermal shift assays allow observation of binding. However, binding does not always
equate to activity. An enzymatic assay typically follows a decrease in reactant concentration,
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an increase in product concentration, or the formation of a byproduct. Here, for the plate-based
assay, IspD converts MEP to CDP-ME pyrophosphate, which in turn is converted to inorganic
phosphate (Pi) with the enzyme inorganic pyrophosphatase. The EnzChek® Phosphate Assay
kit follows the formation of the inorganic phosphate through a reaction with 2-amino-6mercapto-7-methylpurine riboside (MESG) and the enzyme purine nucleoside phosphorylase
(PNP). This reaction converts the MESG into ribose 1-phosphate and 2-amino-6- mercapto-7methylpurine resulting in a spectrophotometric shift in a maximum absorbance from 330 nm to
360 nm (Figure 2-3).104,107 Reactions were performed in 50 µL final volumes in 96-well clear
flat bottom plates, and were initiated by addition of 50 ng purified Ec IspD. Absorbance at 360
nm was measured every 31seconds for 20 minutes on a Synergy 2 Multi-Mode plate reader
(BioTek), preheated to 37°C. Final concentration of reagents was as follows: 1x EnzChek®
reaction buffer (50 mM Tris pH 7.5, 1 mM magnesium chloride (MgCl2), 100 µM sodium
azide (NaN3)), 0.2 mM MESG, 1 U/ml PNP, 1 U/mL inorganic Pyrophosphatase (NEB), 200
mM CMP (Sigma), and 50 µM MEP (Echelon).

Figure 2-3 EnzChek® assay reaction. MESG with phosphate being converted into ribose 1-phosphate and 2-amino-6mercapto-7-methylpurine resulting in a spectrophotometric shift of 330 nm to 360 nm.
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Results

Purification of Ec and Bt IspD

Both Escherichia coli and Burkholderia thailandensis IspD were purified using a nickel
affinity column with a 20-500mM gradient elution using imidazole (Figure 2-4). Fractions
associated with the UV absorbance peak in the chromatogram, verified with a NanoDrop 2000c
spectrophotometer (Thermo Scientific), were combined and concentrated to 10 mL using a spin
concentrator. The resulting concentrate was further purified using a size exclusion
chromatography column (Superdex 75 HiLoad 26/60), and fractions related to the UV
absorbance peak of IspD were collected, combined, and concentrated (Figure 2-5). The
protein was aliquoted and stored at -80°C until needed for thermal shift (DSF), circular
dichroism and enzymatic assays.

A

B

Figure 2-4 Chromatograms of HisTrap affinity column purification for IspD. A) Escherichia coli and B) Burkholderia
thailandensis.
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Figure 2-5 Chromatograms of size exclusion chromatography of IspD. Purification (Superdex 75 HiLoad 26/60) for IspD of
both A) Escherichia coli and B) Burkholderia thailandensis.
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Melting Point Determination of IspD

Circular Dichroism was used to determine the thermal stability of Ec and Bt IspD. Prior
to performing CD, 20 mM of each protein was dialyzed in four liters of buffer (20 mM
phosphate at pH 7.0 and 150 mM NaCl) overnight. Wavelength scans were run before the
thermal melt to get a baseline reading which confirmed the mainly alpha helical secondary
structure of the proteins. Full scans were repeated post-thermal melt to characterize the protein’s
reversibility (Figure 2-6 and 2-7). Both species show loss of secondary structure which may
suggest the thermal unfolding to be non-reversible under the conditions of the experiment. The
thermal stability of each of the proteins was observed at a single wavelength over a temperature
range of 25-100°C (Figure 2-8 and Figure 2-9). The melting temperature (Tm) was determined to
be approximately 66°C for Ec IspD and 53.5°C for Bt IspD, which will be used as reference
temperatures for further thermal shift assays.
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Figure 2-6 CD wavelength scans for Ec IspD for pre- (squares) and post- (x) unfolding.
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Figure 2-7 CD wavelength scans for Bt IspD for pre- (squares) and post- (x) unfolding.
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Figure 2-8 Thermal unfolding of Ec IspD. Melting temperature determined to be 65.9 ± 0.1
°C.
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Figure 2-9 Thermal unfolding of Bt IspD. Melting temperature determined to be 53.5 ± 0.1
°C.
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Thermal Shift of IspD to Determine Binding of Compounds

Prior to testing compounds directly against IspD, a concentration test was performed to
determine the lowest concentration of IspD that would still provide a reasonable change in signal
upon unfolding (Figure 2-10). Comparing the melting temperature with and without the
presence of compound can result in a thermal shift, which may indicate binding. The oxadiazole
series were evaluated with very little observed thermal shifts against Ec IspD (Table 2-2).
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Figure 2-10 Thermal unfolding of Ec IspD with and without a compound. Black squares
indicate Ec IspD with 2% DMSO as a baseline control. Red Xs is Ec IspD in the presence of
50 µM HGN-0446.
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Table 2-2 Thermal shift results for indole oxadiazole series (40 μM) against Ec IspD.

Sample
Ec IspD

Structure

Melting Temp (°C) Change
68.0 ± 0.4
0

207

68.0 ± 0

0 ± 0.4

209

68.0 ± 0

0 ± 0.4

211

68.3 ± 0.4

0.3 ± 0.6

213

68.3 ± 0.4

0.3 ± 0.6

214

68.3 ± 0.4

0.3 ± 0.6

215

68.3 ± 0.4

0.3 ± 0.6

221

68.3 ± 0.4

0.3 ± 0.6

223

68.5 ± 0.7

0.5 ± 0.8

239

68.5 ± 0

0.5 ± 0.4
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Binding Studies of Bt IspD with CTP

ITC studies were performed to observe the dissociation constant along with
thermodynamic properties of the reactant CTP with Bt IspD (Figure 2-11). Due to the low
affinity, the binding stoichiometry was fixed at two CTPs per dimer during data analysis. The
ΔHº of CTP showed to have a value of -6.991 ± 1.749 kcal/mol and an unfavorable entropic
contribution of -TΔS of 5.6 ± 1.838. KD app of CTP was shown to be in the millimolar range
(Table 2-3).
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Figure 2-11 ITC titration of CTP with Burkholderia thailandensis IspD. Conditions were
pH 7.4 and 25°C to determine KDapp values.

Table 2-3 Thermodynamic analysis of CTP binding to Bt IspD by ITC.
Compound pH
CTP

7.4

K

KDapp (mM)

210.5 ± 188.0

4.8 ± 4.2

N
2.0 ± 0
(Fixed)

ΔG°
(kcal/mol)

ΔH°
(kcal/mol)

-TΔS
(kcal/mol)

-3.2 ± 2.5

-69.9 ± 1.7

66.8 ± 1.8
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Discussion

Circular dichroism thermal stability studies of IspD for both E. coli and B. thailandensis
have shown IspD has melting temperatures suitable for thermal shift assays. Thermal shift
assays were performed on potential inhibitors from the pyrazolopyrimidine and the oxadiazole
series which were designed off the fragment hits from the STD-NMR screening. The thermal
shift studies did not show any significant stabilization or destabilization caused by the
compounds on IspD. There are several reasons why there was no observed stabilization changes
to the IspD enzyme. These thermal shift assays were performed against a different species of
IspD compared to the binding studies of the STD-NMR screening which was performed against
M. tuberculosis. Another possibility is that the thermal shift assay compound concentration was
40 µM which could be too low of a concentration to show any stabilization or destabilization to
the enzyme considering known inhibitors bind to the active site in the millimolar range. An
enzymatic assay was optimized for Ec IspD to evaluate several of the compounds to determine if
any have any inhibition activity, however there was no significant activity shown. ITC results of
Bt IspD with CTP revealed weak binding to the cofactor. This weak binding could indicate why
the known inhibitors have such a weak IC50 values against IspD.
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CHAPTER 3

DISCOVERY OF SMALL MOLECULE ENZYME INHIBITORS OF E. COLI ISPD VIA

HIGH-THROUGHPUT SCREENING

Within drug discovery, there are two main strategies for discovering hit compounds:
knowledge-based design and random screening. Knowledge-based design is based on
information of the target, which could be a known inhibitor or substrate that can be mimicked or
perhaps a crystal structure of a compound/protein complex.108,109,110 Conversely, random
screening does not require prior knowledge of the target, and requires screening libraries of
compounds with a variety of structures and bioactivity.111,112
This chapter outlines the screening of the MicroSource Spectrum library using the
thermal stability assay from chapter 2 to evaluate 2,560 compounds which consists of 1040 drugs
that have made clinical trials stage in the US, 240 international drugs that were marketed in
Europe and Asia, and the remaining compounds either natural products or derivatives.113 The
compounds that showed a shift in the stability of IspD were evaluated further using the
EnzChek® enzymatic activity assay.
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Results

Thermal Shift Results

The library based screening technique in conjunction with the thermal shift assay used in
Chapter 2 was implemented to evaluate compounds from Spectrum collection. Out of the 2,560
compounds there were 48 hit compounds that displayed a change in the observed melting
temperature, ranging from +3.53°C (thimerosal) to -13.53°C (cadmium acetate) (Table 3-1).
Thimerosal (+3.53°C) and Zinc Pyrathione (-7.72°C) were evaluated further based on the clarity
of the unfolding profile. Specifically, each compound was broken down into core structures to
determine which portion of the compound affected the thermal stability. To study thimerosal,
thiosalicylic acid and ethyl mercuric chloride were evaluated (Figure 3-1). The results of the
assay revealed that the ethyl mercuric chloride portion of thimerosal affected the stability of the
enzyme (Table 3-2). Zinc pyrathione was simplified to 2-mercaptopyridine-N-oxide to
determine if the zinc was the driving force for the destabilization of Ec IspD (Figure 3-2).
Thermal shift results revealed that 2-mercaptopyradine-N-oxide did not have an effect on the
thermal stability (Table 3-3). Therefore, similar to the thimerosal, it appears that the metal is the
prime factor on the stability of the enzyme.
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Table 3-1 Thermal shift results of IspD from E. coli against compounds in the MicroSource
Spectrum Collection.

Spectrum Collection Hits

Structure

Δ°C

THIMEROSAL

3.53

HEXYLRESORCINOL

1.82

GOSSYPETIN

1.45

MORIN

1.34

ISOLIQUIRITIGENIN

1.23

DIETHYLSTILBESTROL

0.79

OXICONAZOLE NITRATE

0.46

continued on following page

71
Table 3-1 (continued)

COENZYME B12

-0.99

MECYSTEINE
HYDROCHLORIDE

-1.36

4-ACETOXYPHENOL

-1.37

THONZONIUM BROMIDE

-1.42

4,4'DIMETHOXYDALBERGIONE

-1.44

SANGUINARINE SULFATE

-1.52

PRISTIMERIN

-1.61

continued on following page
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Table 3-1 (continued)

GARCINOLIC ACID

-1.62

PLUMBAGIN

-1.69

DISULFIRAM

-1.86

ZINC UNDECYLENATE

-2.24

OLTIPRAZ

-2.27

ACETYL ISOGAMBOGIC
ACID

-2.27

continued on following page
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Table 3-1 (continued)

1,4-NAPHTHOQUINONE

-2.43

HAEMATOXYLIN
PENTAACETATE

-2.47

AUROTHIOGLUCOSE

-2.58

TENATOPRAZOLE

-2.62

CAPTAN

-2.70

PHENYLMERCURIC
ACETATE

-3.13

continued on following page
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Table 3-1 (continued)

PACLITAXEL

-3.37

HYDROQUINONE

-3.37

HAEMATOXYLIN

-3.44

CEDRELONE

-3.57

CEAROIN

-3.96

GARDENIN B

-4.06

CHLORANIL

-4.10

continued on following page
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Table 3-1 (continued)

OBTUSAQUINONE

-4.20

FRAXETIN

-4.56

2,5-DIHYDROXY-3,4DIMETHOXY-4'ETHOXYBENZOPHENONE

-4.70

APOMORPHINE
HYDROCHLORIDE

-5.29

BRONOPOL

-5.31

SIROLIMUS

-7.20

continued on following page
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Table 3-1 (continued)

DIHYDROFISSINOLIDE

-7.65

PYRITHIONE ZINC

-7.72

CARNOSIC ACID

-8.24

AGARIC ACID

-8.55

7-DEACETYLKHIVORIN

-10.15

CISPLATIN

-10.15

continued on following page
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Table 3-1 (continued)
METHYL 7DESHYDROXYPYROGALLIN4-CARBOXYLATE

-11.43

beta-DIHYDROGEDUNOL

-13.47

CADMIUM ACETATE

-13.53
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Figure 3-1 Thimerosal broken into thiosalicylic acid and ethyl mercuric chloride.

Table 3-2 Evaluation of thiosalicylic acid and ethyl mercuric chloride on Ec IspD.

Sample

Melting Temp (°C)

Δ°C

IspD Ec DMSO
Ethylmercuric Chloride
Ethylmercuric Chloride w/ Enzyme
Thiosalicylic Acid
Thiosalicylic Acid w/ Enzyme
Thimerosal
Thimerosal w/ Enzyme

69.0 ± 0.3
NA
73.0 ± 0.3
NA
68.5 ± 0
NA
73.5 ± 0.3

0
NA
4.0 ± 0.4
NA
-0.5 ± 0.3
NA
4.5 ± 0.4
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Figure 3-2 2-mercaptopyrimidine-N-oxide to be evaluated to determine dependence on the
zinc.

Table 3-3 2-mercaptopyradine-N-oxide effect on thermal stability of Ec IspD.

Sample

Melting Temp (°C)

Δ°C

IspD Ec

68.0 ± 0

0

Zinc pyrithione

58.5 ± 0.3

-9.5 ± 0.3

2-mercaptopyradine-N-oxide

67.5 ± 0.3

-0.5 ± 0.3
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EnzChek® Assay Results

EnzChek® was performed as described in Chapter 2. The 48 compounds, which altered
the stability of Ec IspD, were evaluated further with an enzymatic assay to determine potential
inhibitory activity. Dose response curves found three compounds with IC50 values in the high
micromolar range. Thimerosal, which was used as a preservative in vaccines, showed an IC50 of
381 ± 12 μM (Figure 3-3). Isoliquiritigenin, a natural chalcone, has an IC50 of 279 ± 12 μM
(Figure 3-4). Carnosic acid, a preservative in food, showed an IC50 of 794 ± 100 μM (Figure 3-5.
The EnzChek® assay has a phosphate sensitivity of 2-150 μM, to ensure there is no interference
caused by assay components three standards were performed on each plate: buffer only, without
CTP and without MEP.106 These standards confirmed that there was no phosphate
contamination.
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Figure 3-3 Thimerosal DRC against Ec IspD.

Figure 3-4 Isoliquiritigenin DRC against Ec IspD.
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Figure 3-5 Carnosic Acid DRC against Ec IspD.
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Discussion

The screening of compound libraries is an invaluable tool for hit discovery. This
technique allows screening against a wide variety of chemical structures, beyond the knowledgebased compounds developed. The MicroSource Spectrum Collection was evaluated against Ec
IspD using the thermal stability assay, and 48 changes in stabilization were observed. The range
of thermal shifts were from +3.53 (thimerosal) to -13.53 (cadmium acetate). Thimerosal and zinc
pyrathione were selected for additional studies due to their unfolding profiles. Each of these two
compounds were dissected, which revealed that the metals in the compounds were the driving
force for the thermal stability change.
An enzymatic assay was performed against the 48 compounds that showed a stability
change to determine if any had any activity against Ec IspD. Three compounds displayed
inhibition in the high micromolar range: thimerosal (381 ± 12 μM), isoliquiritigenin (279 ± 12
μM) and carnosic acid (794 ± 100 μM). Thimerosal, which shows modest activity against the Ec
IspD, is a well-known organomercurial preservative that has been subject to much controversy of
its toxicity and its use has been greatly reduced over the years and some countries have banned
its use entirely.114 It is this reason why this compound may not be ideal to continue studies with.
Carnosic acid, a three ring abietane found in rosemary, has shown to have antimicrobial
properties and is commonly found in oral care products such as mouthwash and toothpaste.115
This compound, which also has modest activity, is not an ideal candidate for further investigation
due to the catechol moiety which tends to create prolific binding properties, reducing
specificity.116 Isoliquiritigenin, a chalcone found in licorice, has shown to have a wide array of
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properties from anti-cancer to anti-inflammatory activities.117 This compound would be the most
ideal candidate, out of the three, to investigate further to develop a possible lead compound.
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CHAPTER 4

BIOCHEMICAL AND STRUCTURAL CHARACTERIZATION OF ISPE AND

EVALUATION OF INHIBITORS

Currently, IspE has several known inhibitors in the low to mid micromolar range against
E. coli, however there is no known inhibitors against B. thailandensis making it an attractive
target for novel inhibitor discovery (Figures 4-1 and 4-2). There are several inhibitors that
mimic the CDP-ME substrate and bind to the substrate binding site. Compound 9 directly
mimics the substrate site with the benzimidazole coordinating the same as the methylerythritol in
the substrate.118 Compounds 10-14 also utilize the substrate’s cytidine diphosphate pocket for
the pyrimidinone along with exploiting a nearby lipophilic pocket with functional groups in the
5’ position.119,120,121,122 Compound 15 was developed with the attempt of bridging both the ATP
and the CDP-ME binding pockets obtaining low micromolar activity against Ec IspE.123 A
computational high throughput screen of over two million compounds with drug-like properties
against the active site of IspE yielded compound 16 which showed 80% activity at 20 μM against
Ec IspE.124 In the same study, small molecule inhibitors of the
galactose/homoserine/mevalonate/phosphomevalonate (GHMP) kinase superfamily were
screened against Ec IspE which found compounds 17 and 18 in the low micromolar range.
Compounds 19-21 were determined from a non-substrate-like inhibitor screen showing the
compounds to have low micromolar activity against Ec IspE.125 Finally, compound 22 was
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found to have bleaching herbicidal properties with activity against L. esculentum in the singledigit micromolar range.90
The two chemical series that were identified from the NMR fragment screening, the
pyrazolopyrimidines and oxadiazoles, were evaluated further using the thermal shift assay. An
enzymatic assay was developed and optimized to study these compounds for activity against
both E. coli and B. thailandensis. ITC will determine dissociation constants of promising
compounds.
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Figure 4-1 Known inhibitors of Ec IspE.118,119,120,121,122,123,124

88

Figure 4-2 More known inhibitors of Ec IspE.124,125,90
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Methods
IspE Expression and Purification of E. coli and B. thailandensis126

The Ec IspE gene in parent vector pET14b (obtained from Dr. Karen Meyers lab). The
Bt IspE gene was obtained from the SSGCID (ButhA. 00725.a. A1) within the parent vector
AVA0421. Each parent vector introduces the same antibiotic resistance and restriction sites as
the IspD. Also, similar to IspD expression (Chapter 2), the vectors were transformed into
BL21(DE3) competent cells. Both DNA sequences were verified through University of Chicago
CRC-DNA sequencing facility (Table 4-1). The transformed cells were grown on LB agar
plates with 100 µg/ml of amp for selection of the expression plasmid, and a single colony was
chosen to inoculate a five mL of LB (100 µg/ml amp). This five mL sample was incubated
overnight at 37°C while shaking at 235 RPM. A 50 mL LB (100 µg/ml amp) subculture was
inoculated with the overnight culture. This subculture was grown at 37°C with shaking (235
RPM) until reaching an OD600 in a range of 0.5-0.8. Once at mid-log, the cell culture is induced
with IPTG to a final concentration of 1.0 mM. The temperature is dropped to 20°C and the cells
were grown for 16 hours while shaking at 235 RPM. After the 16 hours, the bacterial cells were
pelleted using centrifugation at 8,000 RPM for 15 minutes and stored at -20°C.
Purification for both species of IspE was performed as described for IspD. Affinity
chromatography was executed using a HisTrap HP nickel affinity IMAC column (GE Healthcare
Life Sciences) with a BioLogic LP (Bio-Rad Life Sciences) fast protein liquid chromatography
(FPLC) system. Size exclusion chromatography performed with a Superdex 75 HiLoad 26/60
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size exclusion column (GE Healthcare Life Sciences). Buffer systems were identical for all
enzymes as described in Chapter 2.

Table 4-1 Verified DNA and protein sequences of both Escherichia coli IspE and Burkholderia thailandensis IspE.
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Thermal Stability Assays

All thermal stability assays were completed identical to IspD using circular dichroism
and differential scanning fluorimetry.

Enzyme Inhibition Determination with Kinase-Glo® Luminescent Assay

Similar to the EnzChek® enzymatic assay, determination of activity is fundamental for
evaluation of inhibitor. CDP-ME undergoes phosphorylation by IspE and ATP, leading to the
product CDP-MEP. The Kinase-Glo® assay follows the consumption of the reactant ATP.
The ATP in conjunction with oxygen and beetle luciferin are catalyzed by luciferase with the
cofactor of magnesium to produce oxyluciferin, AMP, carbon dioxide, pyrophosphate, and
creates a luminescence signal (Figure 4-3). This luminescence is directly related to the amount
of ATP within the reaction, as the reaction progresses, the ATP is consumed and the amount of
luminescence is decreased.
All Kinase-Glo® reactions were run using the following conditions (all conditions are
described in final concentrations): 60 mM NaCl, 5 mM MgCl2, 20 mM HEPES, 1 mM DTT,
5% DMSO (for compound suspension), 0.01% BSA, 200 µM CDP-ME, 40 µM ATP, and
either Ec IspE and Bt IspE. All but the substrate CDP-ME are combined and incubated with
the compounds for 10 minutes, before the addition of substrate and incubation (45 minutes,
with shaking, room temperature). After incubation, the Kinase-Glo ® reagent was added in
equal final volume and allowed to develop for 10 minutes. Luminescence was recorded via a
Synergy 2 plate reader.
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It is important to note that reactions involving the compounds and Kinase-Glo® reagent
are important to perform to verify that the compounds are not interfering with luciferase
enzyme in the reagent itself. The oxadiazole series are similar to known luciferase inhibitors,
which tend to resemble the substrate, beetle luciferin.127,128 Most of the oxadiazole series, the
beetle luciferin and the resembling known inhibitor (D-luciferin, 6-methyl ether) all have the
core structure of benzothiazole. However, the difference is that instead of the oxadiazole, the
inhibitor and substrate have a dihydrothiazole.

Figure 4-3 Kinase-Glo® assay monitors kinase activity by observing ATP consumption. ATP interacts with the beetle
luciferin and oxygen to create a luminescence. As the reaction progresses, the kinase uses up the ATP, which in turn reduces
the luminescence.
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ITC Binding Studies

All ITC experiments were performed under the same conditions as described in Chapter
2. Compounds were dissolved in DMSO and brought to concentration with the dialysis buffer,
with a maximum DMSO concentration of 10% by volume which was matched between ligand
and enzyme, and centrifuged at 10,000 RPM for 10 minutes. The dialysis buffer was used for
all sample dilutions to ensure buffers matching between the titrant and titrate, thus minimizing
the excess heat due to buffer mismatch. ITC experiments were performed with IspE in the cell
and ligand in the syringe. The initial injection volume was 2 µL (omitted) followed by 27 10
µL injections, every 240 seconds. Samples were run at 25°C, at pH 7.4, with a stirring speed of
307 RPM. Dilution runs were performed to allow determination of background heats caused
by solution mismatch and instrument noise. Dilution runs were performed with ligand (at the
same concentration as in the experiment run) in the syringe titrated into the dialysis buffer in
the cell. Data were fit using OriginPro 7 with the ITC add-on by the manufacturer.
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Results and Discussion

Expression of IspE for Both E. coli and B. thailandensis Results

IspE enzymes were purified using a nickel affinity column with a 20-500mM gradient
elution using imidazole. Fractions associated with the UV absorbance peak in the
chromatogram, verified with a NanoDrop 2000c spectrophotometer (Thermo Scientific), were
combined and concentrated to 10 mL using a spin concentrator (Figure 4-4). The resulting
concentrate was further purified using a size exclusion chromatography column (Superdex 75
HiLoad 26/60), and fractions related to the UV absorbance peak of IspD were collected,
combined, and concentrated (Figure 4-5).

Figure 4-4 Chromatograms of HisTrap affinity column purification for IspE. A) Escherichia coli and B) Burkholderia
thailandensis.
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Figure 4-5 Chromatograms of size exclusion chromatography for IspE. Purification (Superdex 75 HiLoad 26/60) for IspE of
both A) Escherichia coli and B) Burkholderia thailandensis.
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Melting Point Determination of IspE

Circular Dichroism was used to determine the thermal stability of Ec and Bt IspE.
Wavelength scans were run before the thermal melt to get a baseline reading which confirmed
the mainly alpha helical secondary structure of the proteins. Full scans were repeated postthermal melt to characterize the protein’s reversibility (Figure 4-6 and 4-7). Both species show
loss of secondary structure which may suggest the thermal unfolding to be non-reversible under
the conditions of the experiment. The thermal stability of each of the proteins was observed at a
single wavelength over a temperature range of 25-100°C (Figure 4-8 and Figure 4-9). The
melting temperature (Tm) was determined to be approximately 50°C for Ec IspE and 46°C for Bt
IspE, which will be used as reference temperatures for further thermal shift assays.
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Figure 4-6 CD wavelength scans for Ec IspE for pre- (squares) and post- (x) unfolding.
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Figure 4-7 CD wavelength scans for Bt IspE for pre- (squares) and post- (x) unfolding.
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Figure 4-8 Thermal unfolding of Ec IspE. Melting temperature determined to be 50.3 ± 0.4
°C.
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Figure 4-9 Thermal unfolding of Bt IspE. Melting temperature determined to be 45.8 ± 0.3
°C.
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Thermal Shift Results

Thermal stability assay performed as described in Chapter 2. The range of melting point
shifts for pyrazolopyrimidines are from -1.5°C to +4°C. The range for the oxadiazole series was
much more diverse with a range of -0.5°C to +6.5°C (Table 4-2).

Table 4-2 Thermal shift assay results for pyrazolopyrimidines and oxadiazoles against Bt
IspE.

DSF Bt IspE
Bt IspE

Tm

45.0 ± 0.3°C

GG Compounds

RT Compounds

Compound
139
141
142
216
217
218
220
222
224
226
234

Tm
46.0 ± 0.3
46.5 ± 0
45.0 ± 0.5
46.0 ± 0.3
45.5 ± 0.3
43.5 ± 0.3
45.5 ± 0
45.5 ± 0.3
45.5 ± 0.3
46.0 ± 0.5
46.0 ± 0

Δ°C
1.0 ± 0.4
1.5 ± 0.3
0 ± 0.6
1.0 ± 0.4
0.5 ± 0.4
-1.5 ± 0.4
0.5 ± 0.3
0.5 ± 0.4
0.5 ± 0.4
1.0 ± 0.6
1.0 ± 0.3

Compound
333
779
810
811
824
825
826
832
833
834
835

Tm
48.0 ± 0.3
46.0 ± 0.3
48.0 ± 0.3
45.0 ± 0.3
45.0 ± 1.0
44.5 ± 0.3
47.5 ± 1.0
44.5 ± 1.0
45.5 ± 0.5
45.0 ± 0.3
45.5 ± 0.3

Δ°C
3.0 ± 0.4
1.0 ± 0.4
3.0 ± 0.4
0 ± 0.4
0 ± 1.0
-0.5 ± 0.4
2.5 ± 1.0
-0.5 ± 1.0
0.5 ± 0.6
0 ± 0.4
0.5 ± 0.4

238
277

45.0 ± 0
45.0 ± 0.3

0 ± 0.3
0 ± 0.4

836
837

45.0 ± 0
47.5 ± 0.3

0 ± 0.3
2.5 ± 0.4

279

45.5 ± 0.3

0.5 ± 0.4

838

47.0 ± 0.3

2.0 ± 0.4

372
373

45.5 ± 0
45.0 ± 0.3

0.5 ± 0.3
0 ± 0.3

839
840

47.5 ± 0.5
48.5 ± 0.3

2.5 ± 0.6
3.5 ± 0.4

374

46.0 ± 1.0

1.0 ± 1.0

813

51.5 ± 0.5

6.5 ± 0.6

377

49.0 ± 0

4.0 ± 0.3
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Kinase-Glo® Enzymatic Assay Results

Pyrazolopyrimidines and oxadiazoles were evaluated in an enzymatic assay against both
E. coli and B. thailandensis. The oxadiazole series, which were screened, have a structure
similar to the luciferin reactant in the Kinase-Glo® reagent. To verify that the compounds are
not interacting with the luciferase, involved in the secondary reaction which converts the beetle
luciferin to oxyluciferin, a separate reaction is run sans enzyme (Table 4-3).
This assay is performed with all reagents without enzyme and compounds concentration
was 250 μM. This verification is necessary to ensure the inhibition values of the compounds are
accurate. The assay results revealed only a few compounds in the pyrazolopyrimidine series
possessed inhibition activity with IC50 values in the high micromolar range (Table 4-4). The
oxadiazole series showed a greater range in activity from low to high micromolar with the
greatest activity being from compound HGN-0333 at 3 ± 0.3 μM for E. coli and 28 ± 6.5 μM for
B. thailandensis (Table 4-5).

Table 4-3 Verification of compounds against Kinase-Glo® assay. This was performed to
determine if the compounds were interfering with the luciferase within the reagent. All
values recorded in lumens.

Water
462 ± 5

No Enzyme
No Compound
444852 ± 13059 199108 ± 1792

HGN-0333 Only
446042 ± 13156

HGN-0813 Only
449786 ± 5030
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Table 4-4 Enzymatic activities of pyrazolopyrimidines for IspE.

Compound

Pyrazolopyrimidines
Structure
Ec IC50 (μM) Bt IC50 (μM)

139

>1000

>1000

141

>1000

>1000

142

>1000

285 ± 19

216

>1000

258 ± 6

continued on following page
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Table 4-4 (continued)

217

328 ± 66

>1000

218

>1000

>1000

220

>1000

>1000

222

>1000

>1000

continued on following page
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Table 4-4 (continued)

224

>1000

384 ± 67

226

>1000

>1000

234

>1000

>1000

238

>1000

>1000

continued on following page
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Table 4-4 (continued)

277

>1000

>1000

279

>1000

>1000

372

>1000

>1000

373

>1000

>1000

continued on following page
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Table 4-4 (continued)

374

>1000

>1000

377

>1000

>1000
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Table 4-5 Enzymatic activities of oxadiazoles for IspE.

Compound

Oxadiazole
Structure
Ec IC50 (μM)

Bt IC50 (μM)

207

>1000

>1000

209

>1000

>1000

212

902 ± 150

>1000

333

3 ± 0.3

28 ± 6.5

810

203 ± 35

115 ± 24

811

661 ± 230

221 ± 27

continued on next page
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Table 4-5 (continued)

824

16 ± 6.3

33 ± 13

825

317 ± 88

563 ± 170

826

>1000

>1000

832

>1000

>1000

833

405 ± 49

>1000

834

22 ± 8.8

106 ± 17

continued on next page
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Table 4-5 (continued)

835

656 ± 120

519 ± 100

836

52 ± 29

147 ± 24

837

500 ± 480

>1000

838

700 ± 210

807 ± 550

839

300 ± 210

413 ± 270

840

310 ± 85

349 ± 25
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Binding Studies of Bt IspE with HGN-0333

ITC studies were performed to observe the dissociation constant along with
thermodynamic properties of the oxadiazole compound HGN-0333 with Bt IspE (Figure 4-10).
The experiment showed a binding stoichiometry of 0.903 which would indicate that for each
monomer there is one molecule of HGN-0333. The ΔHº of HGN-0333 showed to have a value of
-8.6 kcal/mol and an entropic contribution of -TΔS of -17.8. KD app of HGN-0333 was shown to
be in the nanomolar range (Table 4-6).
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Figure 4-10 ITC titration of HGN-0333 with Burkholderia thailandensis IspE. Conditions
were pH 7.4 and 25°C to determine KDapp values.

Table 4-6 Thermodynamic analysis of HGN-0333 binding to Bt IspE by ITC.
Compound

pH

HGN-0333

7.4

K
2.2E+06 ±
1.5E+06

KDapp
(nM)
455 ±
310

N
0.903 ±
0.078

ΔG°
(kcal/mol)

ΔH°
(kcal/mol)

-TΔS
(kcal/mol)

-8.6

9.1 ± 1.1

-17.8
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Discussion

The two series of compounds: pyrazolopyrimidines and oxadiazoles, were studied against
IspE using a series of assays to determine binding and activity. Thermal shift assays were
performed to determine a potential change of stability to IspE from B. thailandensis. All but one
of the pyrazolopyrimidines showed little to no significant shifts, only HGN-0377 (furan) having
a +4.0°C shift. Oxadiazoles showed to have a larger range of stability shifts with the largest shift
of +6.5°C which was HGN-0813 (standard). These compounds were evaluated with enzymatic
assays to determine activity against both E. coli and B. thailandensis. Similar to the thermal
assay, the pyrazolopyrimidines had very little activity against both species from the enzymatic
assay. The oxadiazoles had greater activity with HGN-0333 (2,4-dichloro) having an IC50 of 3.0
μM against Ec IspE and 28.0 μM against Bt IspE. To ensure that this compound was not
interfering with the luciferase, the reaction was run without the IspE which showed no change in
the signal compared to the control containing all reactants minus the enzyme and a compound.
ITC experiments also verify binding of HGN-0333 showing a KD of 2.2E+06 ± 1.5E+06 and a TΔS of -17.8 kcal/mol which suggests that the reaction is entropically driven which agrees with
predictions of lipophilic pockets.
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CHAPTER 5

SUMMARY, POTENTIAL APPLICATIONS, AND CONCLUSIONS

Antibiotic resistance is rising at an alarming rate with roughly two million infections and
23,000 deaths in 2013.10 With only two new classes of antibiotics being discovered in the last 30
years, there is a great demand for both new compounds and new classes of targets.15 The goal of
this work was to discover novel hit compounds targeting IspD or IspE for E. coli and B.
thailandensis. Currently, there are very few known inhibitors of either IspD or IspE with most
possessing IC50 values in the millimolar range, consequently, great opportunities exist to
discover and design novel compounds that target and disrupt these enzymes.
Initial thermal stability studies provided insight on the melting points of E. coli and B.
thailandensis IspD. A thermal shift assay is an efficient and cost effective way of evaluating a
series of compounds as an initial filter to determine which were evaluated further for enzymatic
activity. Current inhibitors of Ec IspD mimic the substrate, such as fosmidomycin. NMR
fragment screening of the Fragments of Life library against IspD from Mycobacterium
paratuberculosis and IspE from Mycobacterium abscessus showed 102 compounds bound IspD
and 176 compounds bound IspE. Of these known binders, 37 compounds bound to both IspD
and IspE. One of those fragments that bound to both IspD and IspE is the base of the oxadiazole
series which was studied with the thermal shift assay against Ec IspD. This study did not show a
significant shift in the thermal stability. Another class of fragment hits for both enzymes was the
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pyrazolopyrimidines, which again showed no significant thermal stability shifts. Most of these
compounds were evaluated further using an enzymatic activity assay. These compounds showed
weak to no activity against Ec IspD. Isothermal titration calorimetry revealed that the reactant
CTP binds with weak affinity to Ec IspD, which could indicate why compounds have such a
weak affinity for IspD.
To expand the development of novel chemical matter, beyond what was identified using
NMR screening, compounds were evaluated for binding activity against IspD using a thermal
shift assay a library of compounds. The MicroSource Spectrum collection contains about 2,500
compounds of known drugs and natural products. Initial thermal shift results showed stability
shifts for 48 compounds, both positive and negative shifts with a range of +3.53°C (thimerosal)
to -13.53°C (cadmium acetate). Compounds were evaluated further using the enzymatic activity
assay, which revealed a few compounds with high micromolar activity: isoliquiritigenin (IC50 =
279 ± 12 μM), thimerosal (IC50 = 381 ± 12 μM), and carnosic acid (IC50 = 794 ± 100 μM).
While these activities are not very potent, they are more potent than the known E. coli inhibitors
which could be used for future development for more potent inhibitors.
Similar to IspD, IspE was studied using the same techniques against the
pyrazolopyrimidine series and oxadiazole series of compounds. Thermal shift results against B.
thailandensis ranged from +5.5°C (pyrazolopyrimidine with furan functional group) to -4.5°C
(pyrazolopyrimidine with dichlorobenzene). An enzymatic assay was developed and optimized
to evaluate the IspE against E. coli and B. thailandensis further revealing several compounds in
the low micromolar range. The pyrazolopyrimidine series only showed a few compounds in the
high micromolar range, however the oxadiazole series proved more fruitful for a range of
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activity from high to low micromolar. The most potent compound for both species was HGN0333, an oxadiazole with a 2,4-chloro benzene with an IC50 for E. coli and B. thailandensis of
3.0 ± 0.3 and 28.0 ± 6.5 μM, respectively. This compound is an ideal candidate for further
development of more active compounds.
This research provided new insights into the biophysical properties of IspD and IspE
enzymes and methods to evaluate compounds with potential inhibitory activity. A high
throughput thermal shift assay was designed to assess inhibitors for further studies. Enzymatic
assays were developed to further study compounds for both IspD and IspE. Inhibitors of Ec
IspD were discovered to be in high micromolar range from the MicroSource Spectrum collection
which are more potent than low millimolar range. IspE from both E. coli and B. thailandensis
were found to have several inhibitors from the oxadiazole series in the low micromolar range.
These hits could be further developed into more potent leads which could lead to possible future
antibiotics.
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APPENDIX A
Dose response curves of pyrazolopyrimidine compounds against IspE for both
Burkholderia thailandensis and Escherichia coli. Compounds HGN-0139, HGN-0141, and
HGN-0142 were synthesized by Joy Blain. Compounds HGN-0216, HGN-0217, HGN-0218,
HGN-0220, HGN-0222, HGN-0224, HGN-0226, HGN-0234, HGN-0238, HGN-0277, HGN0279, HGN-0372, HGN-0373, HGN-0374, and HGN-0377 were synthesized by Gashaw Goshu.
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Figure A1 Dose response curves of HGN-0139 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A2 Dose response curves of HGN-0141 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A3 Dose response curves of HGN-0142 against A) Burkholderia thailandensis and B)
Escherichia coli

133
A

B

Figure A4 Dose response curves of HGN-0216 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A5 Dose response curves of HGN-0217 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A6 Dose response curves of HGN-0218 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A7 Dose response curves of HGN-0220 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A8 Dose response curves of HGN-0222 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A9 Dose response curves of HGN-0224 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A10 Dose response curves of HGN-0226 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A11 Dose response curves of HGN-0234 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A12 Dose response curves of HGN-0238 against A) Burkholderia thailandensis and B)
Escherichia coli
A

B

Figure A13 Dose response curves of HGN-0277 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A14 Dose response curves of HGN-0279 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A15 Dose response curves of HGN-0372 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A16 Dose response curves of HGN-0373 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A17 Dose response curves of HGN-0374 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure A18 Dose response curves of HGN-0377 against A) Burkholderia thailandensis and B)
Escherichia coli

APPENDIX B
Dose response curves of oxadiazole series of compounds against IspE for both
Burkholderia thailandensis and Escherichia coli. Compounds HGN-0825 and HGN-0833 were
synthesized by Zachary Lazowski, and compound HGN-0826 was synthesized by Ryan Whyte.
Compounds HGN-0207, HGN-0209, HGN-0212, and HGN-0333 were synthesized by Michael
Thompson. Compounds HGN-0810, HGN-0811, HGN-0824, HGN-0832, HGN-0834, HGN0835, HGN-0836, HGN-0837, HGN-0838, HGN-0839, and HGN-0840 were synthesized by
Jeremy Troxell.
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Figure B1 Dose response curves of HGN-0207 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B2 Dose response curves of HGN-0209 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B3 Dose response curves of HGN-0212 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B4 Dose response curves of HGN-0333 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B5 Dose response curves of HGN-0810 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B6 Dose response curves of HGN-0811 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B7 Dose response curves of HGN-0824 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B8 Dose response curves of HGN-0825 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B9 Dose response curves of HGN-0826 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B10 Dose response curves of HGN-0832 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B11 Dose response curves of HGN-0833 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B12 Dose response curves of HGN-0834 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B13 Dose response curves of HGN-0835 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B14 Dose response curves of HGN-0836 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B15 Dose response curves of HGN-0837 against A) Burkholderia thailandensis and B)
Escherichia coli
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Figure B16 Dose response curves of HGN-0838 against A) Burkholderia thailandensis and B)
Escherichia coli
A

B

Figure B17 Dose response curves of HGN-0839 against A) Burkholderia thailandensis and B)
Escherichia coli

150
A

B

Figure B18 Dose response curves of HGN-0840 against A) Burkholderia thailandensis and B)
Escherichia coli

